Response to Comments: MolDX: Pharmacogenomics Testing

This document (A58178) is a response-to-comments notice regarding MolDX Pharmacogenomics Testing and does not itself define coverage criteria. It references LCD DL38394 (comment period 10/30/2019–12/15/2019) and LCD L38294 (notice period 06/18/2020–08/02/2020; effective 08/03/2020) for the applicable coverage policies, which require review for specific indications, limitations, documentation, and frequency rules.

"This document is a response-to-comments notice and does not specify coverage criteria; refer to MolDX: Pharmacogenomics Testing LCD DL38394 and MolDX: Next Pharmacogenomics Testing L38294 for cover..."

Sign up to see full coverage criteria, indications, and limitations.